From the clinical viewpoint, targeting YTHDF2 can concurrently inhibit PD‐L1 and VEGFA to suppress immune evasion and angiogenesis in HCC, which potentiates its translational value as a therapeutic target. Here, VEGFA is linked to hepatocellular carcinoma.